Axogen Q2 Adj EPS $(0.03) Beats $(0.15) Estimate, Sales $38.16M Miss $39.40M Estimate
Portfolio Pulse from totan@benzinga.com
Axogen reported Q2 adjusted EPS of $(0.03), beating the estimate of $(0.15) by 80%. However, the company's sales of $38.16M missed the estimate of $39.40M by 3.16%. This represents a 50% increase in losses and a 10.74% increase in sales compared to the same period last year.
August 07, 2023 | 8:02 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Axogen's Q2 results showed a mixed performance with EPS beating estimates but sales missing. This could lead to mixed investor sentiment.
Axogen's Q2 results showed a better than expected EPS but lower than expected sales. This mixed performance could lead to uncertainty among investors, potentially impacting the stock's short-term performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100